跳到正文
原文
The Lancet 柳叶刀· Chong-Rui Xu, Yan Zhang, Guinan Lin, Haiyong Wang, Qiming Wang, Dingzhi Huang, Yan Yu, Jin Zhou, Hua Zhong, Lin Wu, Lingxiang Liu, Jianchun Duan, Zhiyi He, Yongzhong Luo, Hongxu Liu, Bi Chen, Xinmin Yu, Feng Xue, Qian Chu, Sanxing Guo, Runxiang Yang, Jia Zhong, Haifeng Liu, Longhua Sun, Xiaorong Dong, Haichuan Su, Peng Zhang, Bin Yang, Sisi He, Yuanyuan Ji, Lixin Wan, Xinghua Han, Jingyu Zhang, Fei Qiu, Lulu Yang, Wei Shi, Yi-Long Wu, HERON-Lung01 Investigators·· 25 天前精选AI 评分70

Ruzaltatug rezetecan 对比化疗用于 EGFR 突变型晚期非小细胞肺癌(HERON-Lung01):中国 III 期试验的中期分析

[Articles] Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China

AI 导读

Ruzaltatug rezetecan 在 EGFR-TKI 阻力型 NSCLC 中显著延长 PFS,安全性可管理。

推荐理由

报道了 Ruzaltatug rezetecan 在 EGFR-TKI 阻力型 NSCLC 中的 III 期临床试验结果。

来源:The Lancet 柳叶刀 · thelancet.com